• C, 3 h, 99% yield; c) tetra-O-acetyl DNJ 8 (1.05 equiv), Na(AcO) 3 BH (4.0 equiv), AcOH (catalytic), Na 2 SO 4 (100 weight-%), ClCH 2 CH 2 Cl, 18 h, 53% yield; d) NaOMe (10.0 equiv), MeOH, 18 h, 71% yield. Ts = p-toluenesulfonyl, DMF = N,N -dimethylformamide. • C, 18 h; b) Dess-Martin periodinane (1.0 equiv), CH 2 Cl 2 , 25
• C, 18 h, 75% yield over two steps from S1; c) ethylene glycol (1.3 equiv), TsOH (catalytic), benzene, 95
• C, 12 h, 71% yield; d) H 2 , Pd/C (2.5 weight-%), 1,4-dioxane, 100% yield; e) TsCl (1.1 equiv), Et 3 N (1.3 equiv), DMAP (0.1 equiv), CH 2 Cl 2 . DMAP = N,N -dimethylaminopyridine. In vitro inhibition of GluII by 4. Enzyme activity assays were carried out using rat liver ER GluII with either α-p-nitrophenylglucoside (α-PNPG, A) or fluorescently labelled glycan (B and C) as substrate. The curves show the relationship between ToP-DNJ 4 concentration and inhibition of the enzymatic activity. The iminosugar inhibits the enzymatic catalysis of the reactions independent of substrate, but with differing IC 50 values: 9.0 µm for α-PNPG; 14 µm for Glc 2 Man 7 GlcNAc 2 ; 56 µm for Glc 1 Man 7 GlcNAc 2 .
Supplemental
(A) Huh7.5 (A) Huh7.5 cells were infected with DENV (serotype 2, strain 16681, multiplicity of infection = 0.1) and treated with a titration of ToP-DNJ 4 or 50 µm of tocopherol 3 for 48 h. Infectious virus titer was measured by plaque assay on LLC-MK 2 cells. Counts were normalized to 100% for untreated samples. Neither 4 nor 3 showed an anti-DENV effect at the concentrations tested. (B) Huh7.5 cells were infected with HCV (JFH-1, multiplicity of infection = 2) and treated with a titration of ToP-DNJ 4 or 50 µm tocopherol 3 for 96 h. Infectious virus titer was measured by TCID 50 assay on naïve Huh7.5 cells. Neither 4 nor 3 showed an anti-HCV effect at the concentrations tested. In both panels, each data point represent the mean of triplicates, with error bars showing standard error of the mean (GraphPad Prism). In both cases, the lack of antiviral effect is in concert with the fact that no glucosylated FOS were observed in Huh7.5 cells treated with 4. Mice were treated with a single dose of 4 by oral gavage (PO, 10 mg/kg). The mice were sacrificed at 30 min, 4 h, and 24 h after 4 administration, and the indicated tissues homogenized and analyzed for 4 by HPLC. While serum levels are much lower than those observed for mice treated with 4 by IV, high levels are achieved in the liver and kidney at 0.5 hours. At 4 and 24 h, as in the IV cohort, 4 remains at a higher concentration in the liver than in other tissues. Each data point represents the mean of 3 animals with error bars representing standard deviation (GraphPad Prism). for 18 h. The reaction mixture was then diluted with sat. aq. NaHCO 3 (50 mL) and sat. aq. NaS 2 O 3 (50 mL). The layers were separated, and the aqueous layer extracted with CH 2 Cl 2 (2 × 100 mL). The combined organic layers were washed with sat. aq. NaHCO 3 (100 mL) and brine (2 × 100 mL), dried (MgSO 4 ), filtered, and concentrated under reduced pressure.
General Synthetic Procedures
The residue was purified by flash column chromatography (silica gel, EtOAc:pet ether = 1:2 → 2:3) to give aldehyde S3 (2.85 g, 14.8 mmol, 75% yield from S1) as a colorless oil. S3: ToP-DNJ 4: To a stirred solution of 9 (790.6 mg, 952 µmol, 1.0 equiv) in MeOH (15 mL) at room temperature was added NaOMe (514.6 mg, 9.52 mmol, 10. equiv).
The mixture was stirred at room temerparture for 18 h. 
Enzyme Inhibition Assays
All rat enzymes were isolated from 18-week-old, male Wistar rats, while human lysosomal α-glucosidase was obtained in commercially available form from Sanofi Genzyme. Inhibition of isolated glucosidases was evaluated as described previously. 3 Briefly, maltase, isomaltase, sucrase, and cellobiase were used as partially purified tissue extracts. Inhibition assays for each enzyme were performed with the respective natural substrate, and release of d-glucose measured by Glucose B-test (Wako Diagnostics). Assays of rat ER α-glucosidase II and human lysosomal α-glucosidase inhibition were conducted with α-p-nitrophenylglucoside as substrate; 400 mm Na 2 CO 3 was added to quench these reactions, and the extent of hydrolysis was evaluated as absorbance at 400 nm by spectrophotometer.
ER α-glucosidase I inhibition assays were performed using anthranilic acid-labelled Glc 3 Man 7 GlcNAc 2 as substrate. After terminating the reaction with acetonitrile, protein was removed by centrifugation through a 10 kDa molecular weight cut off filter. The amount of hydrolysis was then quantified by normal phase high performance liquid chromatography analysis of unreacted substrate and product (Glc 2 Man 7 GlcNAc 2 ).
4
ER α-glucosidase II inhibition assays using native-like substrates were performed using anthranilic acid-labelled Glc 2 Man 7 GlcNAc 2 as substrate. After terminating the reaction with acetonitrile, protein was removed by centrifugation through a 10 kDa molecular weight cut off filter. The amount of hydrolysis was then quantified by normal phase high performance liquid chromatography analysis of unreacted substrate and both products (Glc 1 Man 7 GlcNAc 2 and Man 7 GlcNAc 2 ). 
Isolation and Culture of Primary Human MDMΦ
Primary human MDMΦ were generated from human monocytes isolated from buffy coats (NHS Blood and Transplant, surplus to clinical requirements) as described previously 
Cell Viability
Cell viability was measured using the CellTiter 96 R AQ ueous One Solution Cell Prolifera- After the incubation, 20 µL of MTS reagent was added to the 200 µL of media in each well..
After a further one to two hour incubation, the absorbance at 490 nm was measured on a Molecular Devices SpectraMax M5 microplate reader. The endpoint for evaluation was taken when untreated cells had an absorbance reading of approximately 1.
Absorbances were averaged across replicates, and corrected for background by subtracting the value for media-only wells. Each drug treatment was then evaluated as a percentage of untreated cells. This was used to determine the highest nontoxic concentration.
Free Oligosaccharide Assay
FOS analysis was carried out as described previously. 4 Briefly, cells were cultured in 6-well plates with 2 mL of media in each well, with each treatment carried out in triplicate. All assays were performed for 2 d. The primary MDMΦ cells (2 donors) were seeded at a density of 3 × 10 6 cells/well, while all other cell types were seeded at a density of 1 × 10 6 cells/well. At the end of the incubation, cells were washed with phosphate buffered saline (PBS, Gibco, 3 × 1 mL), suspended in 1 mL of H 2 O and subjected to freeze-thaw cycling (3 × 25 to -80 • C) to effect cell lysis. Before purifying the FOS, each sample was analyzed for protein content using the modified Bradford assay. 6;7 Charged species were removed from the sample by mixed bed ion exchange chromatography, and the obtained neutral sample dried by lyophilisation. FOS were fluorescently labelled with anthranilic acid. The product was purified by solid phase extraction using a DPA-6S column (Sigma), followed by Concanavalin A column. The labelled glycans were then analyzed by normal phase high performance liquid chromatography. Retention times and peak area were used to identify and quantify glycans, respectively, by comparison to standards of known identity and molar quantity. FOS quantities were normalized to protein levels.
HCV Antiviral Assay
Huh7.5 cells were seeded in a 96-well plate at a density of 5 × 10 3 cells/well in 100 µL growth media. After an 18 h incubation, the supernatant was removed, and the wells were 
HCV TCID 50 Assay
Huh7.5 cells were seeded in a 96-well plate at a density of 2 × 10 4 cells/well in 100 µL of growth media and incubated for 18 h. The supernatants to be evaluated were diluted 1:10 in growth media, and 7 serial half-log 10 dilutions were subsequently prepared in the same media. 
DENV Plaque Assay
The infectious DENV titres in supernatants collected were evaluated by plaque assay as described previously. 9 Briefly, LLC-MK 2 cells were seeded in confluent monolayers in a 12-well plate. Four 10-fold dilutions of each supernatant to be analyzed were prepared in minimum essential media (MEM, Gibco), supplemented with 100 µg mL −1 streptomycin,
The adherent monolayers were washed once with Hank's buffered salt solution (Gibco), then inoculated with 100 µL of analyte and 100 µL of the supplemented MEM used to prepare the dilutions. The plates were rocked at 20
• C for 90 min, after which the inoculum was removed and nutrient-supplemented primary overlay (1 mL) was added to each well. The overlay was allowed to solidify at 20 • C, before returning the cells to the incubator. After 5 d, nutrient-supplemented, neutral red-containing secondary overlay (1 mL) was added to each well and allowed to solidify at 20 • C, then the cells were returned to the incubator.
After 1 d, plaques were observed and counted from the underside of the plate by eye.
Pharmacokinetics and Biodistribution Study
The study was carried out by Sai Life Science, Ltd. were euthanized by CO 2 asphyxiation, and spleen, brain, liver, kidney, heart, and lung were collected. The tissues were dipped three times in 20 mL fresh PBS, dried on blotted paper and weighed. The samples were then homogenized in ice-cold PBS and stored at -70 • C until analysis. All samples were analyzed by liquid chromatography-tandem mass spectrometry.
Peak areas were used to quantify the amount of 4 present by comparison to a standard curve, and values were subsequently normalized to mass of organ analyzed.
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